Stay abreast with the latest developments in the professional domain along with in-depth analysis through the monthly BCA Journal. Get access to an engaging library of researched publications from the BCAS stable.
Learn MoreExplore past issues of BCA Journal & indulge in a treasure trove of high-quality professional content across format of print, videos & learning events from the BCAS stable.
Learn More
1. TECHNOLOGY
# AI Could Cut 10 Weeks From Cancer Trials. Drugmakers Could Save Millions.
AI-powered systems are increasingly being explored for some of the labour-intensive work involved in running clinical trials.
AI agents could accelerate the clinical development of cancer medicine by approximately 10 weeks while reducing direct operating costs by as much as $5.6 million in late-stage trials.
A Tufts Center for the Study of Drug Development (CSDD) analysis found that AI agents could shorten cancer drug clinical development by about 10 weeks and reduce Phase 3 trial costs by up to $5.6 million. For drugs tested across multiple cancer indications, total benefits could reach $565 million. AI can improve patient recruitment, monitoring, data management, and trial analysis, leading to faster enrollment and quicker database lock. While AI may become a standard tool in clinical trials within 3 to 5 years, human oversight will remain essential, and AI cannot address all challenges in drug development or guarantee clinical success.
(Source: International Business Times – By Matias Civita – 13 August 2026)
